Glial cell line-derived neurotrophic factor protects striatal calbindin-immunoreactive neurons from excitotoxic damage.
The neostriatum is one of the areas with relatively high levels of glial cell line-derived neurotrophic factor (GDNF) messenger RNA expression in the developing and adult brain. GDNF expression in the neostriatum has been suggested to be involved in promoting the survival of nigral dopaminergic neurons, acting as a target-derived neurotrophic factor. However, GDNF messenger RNA expression in the striatum starts several days before dopaminergic and other afferent neurons reach the striatum, suggesting additional trophic effects of this factor on striatal neurons. In the present report, we have examined whether GDNF is able to prevent the degeneration of striatal calbindin- and parvalbumin-immunoreactive neurons in a lesion model of Huntington's disease. Fischer 344 rat 3T3 fibroblast cell line expressing high levels of GDNF (F3A-GDNF) was used to assess the protective effect of this factor, on striatal neurons, against excitotoxicity. Quinolinate (34 nmol) was injected at two different coordinates, and calbindin, parvalbumin and tyrosine hydroxylase immunoreactivity were examined seven days after lesion. Dopaminergic afferents were spared after quinolinate injection, but the number of calbindin- and parvalbumin-immunoreactive neurons was decreased. Interestingly, implantation of F3A-GDNF cells increased the density of tyrosine hydroxylase staining in the intact and also in the quinolinate-lesioned striatum. Furthermore, GDNF partially protected calbindin- but not parvalbumin-immunoreactive neurons from quinolinate excitotoxicity. Instead, mock-transfected fibroblasts did not affect any of these parameters. Our results show that GDNF specifically protects a subpopulation of striatal calbindin-immunoreactive neurons against quinolinate lesion, suggesting that GDNF administration may have a potential therapeutic application in the prevention and treatment of striatonigral degenerative disorders.
Pérez-Navarro
E
E
Department de Biologia Cellular i Anatomia Patològica, Facultat de Medicina, Universitat de Barcelona, Spain.
Arenas
E
E
Reiriz
J
J
Calvo
N
N
Alberch
J
J
D016475:3T3 Cells; D000818:Animals; D064026:Calbindins; D002460:Cell Line; D018691:Excitatory Amino Acid Antagonists / Q000494:pharmacology*; D018846:Excitatory Amino Acids / Q000633:toxicity*; D051100:Glial Cell Line-Derived Neurotrophic Factor; D007150:Immunohistochemistry; D051379:Mice; D017072:Neostriatum / Q000166:cytology / Q000187:drug effects* / Q000378:metabolism; D009414:Nerve Growth Factors / Q000096:biosynthesis / Q000494:pharmacology*; D009419:Nerve Tissue Proteins / Q000096:biosynthesis / Q000378:metabolism* / Q000494:pharmacology*; D009457:Neuroglia / Q000378:metabolism*; D009474:Neurons / Q000187:drug effects*; D017378:Quinolinic Acid / Q000633:toxicity; D051381:Rats; D011916:Rats, Inbred F344; D064030:S100 Calcium Binding Protein G / Q000378:metabolism*
D064026:Calbindins; D018691:Excitatory Amino Acid Antagonists; D018846:Excitatory Amino Acids; C495040:Gdnf protein, mouse; C495041:Gdnf protein, rat; D051100:Glial Cell Line-Derived Neurotrophic Factor; D009414:Nerve Growth Factors; D009419:Nerve Tissue Proteins; D064030:S100 Calcium Binding Protein G; D017378:Quinolinic Acid